Loading...
Loading...
Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd.. Spoken Alpha tracks CYTOF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CYTOF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CYTOF.
curl https://api.spokenalpha.com/v1/companies/CYTOF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.36 | $3.33 | +0.9% | +2.2% | +0.9% |
| Q4 FY2026 | $3.51 | $3.23 | +8.6% | -1.5% | -2.7% |
| Q3 FY2026 | $3.71 | $3.42 | +8.5% | +6.1% | +3.5% |
| Q2 FY2026 | $3.79 | $3.52 | +7.8% | +1.8% | +2.7% |
| Q1 FY2025 | $3.41 | $3.36 | +1.4% | +6.1% | +8.3% |
| Q4 FY2025 | $3.59 | $3.45 | +4.0% | +7.2% | +9.3% |
| Q3 FY2025 | $3.54 | $3.43 | +3.2% | +2.1% | +3.9% |
| Q2 FY2025 | $3.31 | $3.33 | -0.7% | +3.3% | +5.4% |
| Q1 FY2024 | $3.58 | $3.35 | +6.8% | -2.3% | -0.9% |
| Q4 FY2024 | $3.34 | $3.48 | -3.9% | +4.5% | +4.2% |